A candidate antiviral for the treatment of Covid-19 has delivered an 89% reduction in the risk of Covid-19 related hospitalisation or death compared with placebo in a Phase 2/3 clinical study, the developer Pfizer Inc, announced on 5 November. On the recommendation of the trial’s independent data monitoring committee, the study was stopped and data will be sent to the US Food and Drug Administration to support an emergency use authorisation.
